Impact of smoking and brain metastasis on outcomes of advanced EGFR mutation lung adenocarcinoma patients treated with first line epidermal growth factor receptor tyrosine kinase inhibitors

• Main Authors: Jain A., Lim C., Gan E.M., Ng D.Z., Ng Q.S., Ang M.K., Takano A., Chan K.S., Tan W.M., Kanesvaran R., Toh C.K., Loo C.M., Hsu A.A.L., Devanand A., Lim C.H., Koong H.N., Koh T., Fong K.W., Yap S.P., Kim S.W., Chowbay B., Oon L., Lim K.H., Lim W.T., Tan E.H., Tan D.S.W.
• Other Authors: SURGERY
• Format: Article
• Published: Public Library of Science 2020
• Subjects: afatinib; erlotinib; gefitinib; vasculotropin; epidermal growth factor receptor; protein kinase inhibitor; advanced cancer; age; aged; Article; Asia; brain metastasis; cancer palliative therapy; cancer staging; cancer survival; cohort analysis; controlled study; correlational study; disease association; EGFR gene; female; follow up; human; lung adenocarcinoma; major clinical study; male; overall survival; progression free survival; retrospective study; sex difference; smoking; treatment outcome; adenocarcinoma; adult; adverse effects; antagonists and inhibitors; brain tumor; demography; disease course; disease free survival; dna mutational analysis; drug effects; enzymology; genetics; Kaplan Meier method; Lung Neoplasms; middle aged; multivariate analysis; mutation; reflex; secondary; very elderly; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cohort Studies; Demography; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Receptor, Epidermal Growth Factor; Reflex; Smoking; Treatment Outcome
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/165697
• Institution: National University of Singapore

10.1371/journal.pone.0123587